AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00813813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
Study NCT02292017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolization of intracranial aneurysm
Description: Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
Study NCT04984707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX0826
Description: AR antagonist
Study NCT04984707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of KX-826
Study NCT01055730 — intervention group
Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: Structured education and supervised exercise program, lasting between 6 and 9 weeks.
Study NCT04699955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deviance Regulation Theory
Description: In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
Study NCT02331602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
Study NCT02331602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
Study NCT03197012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-TOC
Description: Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
Study NCT03197012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-TOC
Description: In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
Study NCT01956422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure(CPAP)
Study NCT01956422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi Mask FiO2 40%
Study NCT01176721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: t-VNS verum
Description: Active stimulation of the left auricle by t-VNS
Study NCT01176721 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: t-VNS placebo
Description: Sham stimulation of the left auricle with the t-VNS device
Study NCT03582774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care
Study NCT03582774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03582774 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study NCT03582774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT02583425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-11 Injection
Study NCT01053195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
Study NCT00687999 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pegylated interferon alpha and ribavirin
Description: standard pegylated interferon alpha and ribavirin
Study NCT04088721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD17002
Description: LTh(αK) as immunomodulator
Study NCT04088721 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Formulation Buffer
Description: Formulation buffer
Study NCT03440749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: luminous stimuli
Description: The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
Study NCT03440749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: luminous stimuli
Description: The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: serum level of 50 to 125 ug/L
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: serum level of 50 to 125 ug/L
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valproate
Description: serum level of 50 to 125 ug/L
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: serum levels of 0.6 to 1.2 mmol/L
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: serum levels of 0.6 to 1.2 mmol/L
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: serum levels of 0.6 to 1.2 mmol/L
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 to 6 mg/day
Study NCT03738813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gloreha Aria
Description: Device offers specific programs that help patients to move arm, wrist and fingers
Study NCT03738813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Conventional occupational therapy
Study NCT04447001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-chi prime (TCP)
Description: TCP is a 6-week twice-weekly simplified tai chi class of 1.5 hr per session with two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
Study NCT03159871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratafix suture
Description: Stratafix barbed sutures during C-Sections.
Study NCT03159871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl suture
Description: Standart Vicryl suture during C- Sections.
Study NCT00712543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactulose (Kristalose®)
Description: Crystals to be dissolved in water and taken as prescribed.
Study NCT00712543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liquid lactulose
Description: Liquid to be taken as prescribed.
Study NCT03436693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin 100mg orally once daily
Study NCT03436693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily
Study NCT03406559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: orthodontic treatment
Description: fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
Study NCT03403829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine maintenance chemotherapy
Study NCT03403829 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: standard chemoradiotherapy
Description: standard chemoradiotherapy
Study NCT03403829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard chemoradiotherapy
Description: standard chemoradiotherapy
Study NCT03650933 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: 6 cycles(each cycle is 3 weeks)
Study NCT02659202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulator System
Description: The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
Study NCT03836781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
Study NCT03836781 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chlorhexidine 2%
Description: Chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
Study NCT03662919 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Administered as specified in the treatment arm.
Study NCT03662919 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Administered as specified in the treatment arm.
Study NCT04275687 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic irradiation
Description: For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost.
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 to 6 mg/day
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 5 to 25 mg/day
Study NCT01977300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5 to 25 mg/day
Study NCT01977300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: manufactured to mimic risperidone and olanzapine
Study NCT01977300 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: manufactured to mimic risperidone and olanzapine
Study NCT04419402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-PSMA
Description: Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.~Treatment administered every 6 weeks, x 4 cycles.
Study NCT04419402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg (four 40 mg capsules) daily.
Study NCT04419402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg (four 40 mg capsules) daily.
Study NCT01566331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby-guardTM
Description: Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
Study NCT00863655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Study NCT00863655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg orally daily.
Study NCT00863655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg orally daily.
Study NCT00863655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus Placebo
Description: Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Study NCT00644202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Sessions
Description: Counseling Sessions at each study visit around diet and physical activity from a registered dietician
Study NCT00644202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Website
Description: Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
Study NCT00644202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling Calls
Description: 5 telephone calls with a health counselor, lasting 15-20 minutes each.
Study NCT04351503 — intervention group
Intervention type: OTHER
Intervention: Study A
Description: Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.
Study NCT04351503 — intervention group
Intervention type: OTHER
Intervention: Study B
Description: Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.
Study NCT04275687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
Study NCT05180578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goat milk diet
Description: Elimination of cow milk from diet . Goat milk containing diet.
Study NCT04351503 — intervention group
Intervention type: OTHER
Intervention: Study C
Description: Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.
Study NCT04351503 — intervention group
Intervention type: OTHER
Intervention: Study D
Description: Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment:~1. Lopinavir/Ritonavir~2. Hydroxychloroquine~3. Tocilizumab~4. Eculizumab~5. Ruxolitinib~6. Remdesivir~7. Treatment with convalescent plasma blood count, blood chemistry and pulmonary function test (collected on a routine basis during hospitalization and in the outpatient setting).
Study NCT04479436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
Study NCT04463420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHR160 Spray
Description: One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.
Study NCT04463420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive a placebo spray every hour. This process will continue for 10 days.
Study NCT04463420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
Study NCT04463420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
Study NCT05917834 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nipple sparing mastecomy with different incision placements
Description: Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
Study NCT01702285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-101
Description: 200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
Study NCT04560985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrophilic fissure sealant
Description: Hydrophilic fissure sealant on first molars
Study NCT01202305 — intervention group
Intervention type: PROCEDURE
Intervention: Lymph node biopsy
Description: Inguinal lymph node biopsy
Study NCT04560985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrophobic fissure sealant
Description: Hydrophobic fissure sealant on first molars
Study NCT00544401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnopuncture (Hypnosis+Acupuncture)
Description: hypnosis and acupuncture
Study NCT02685358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach
Description: Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
Study NCT02685358 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Mental Health Integrated Care as Usual
Description: Existing primary care mental health integrated treatment will serve as the comparison condition
Study NCT03045432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-teaching
Description: By watching a video specially designed by a rehabilitation team, the participants may learn how to position their affected arm properly (30 minutes per time, twice a day for five days in a week), how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly (15 minutes per time, twice a day for five days in a week), and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy.
Study NCT04317508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topicale GelPatch (Benzocaine 18%)
Description: Intervention group
Study NCT04317508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzocaine oral gel 20%
Description: control group
Study NCT01197508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Twice daily for 8 weeks.
Study NCT01197508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 8 weeks.
Study NCT03295318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted study formulation NmCV-5
Description: Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.